eosinophil proliferation

Mepolizumab (SB 240563) is a humanized monoclonal antibody that neutralizes IL-5, and can be utilized in research on severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.

TAK-661 is an inhibitor of eosinophil chemotaxis (eosinophil chemotaxis) that significantly alleviates late-phase bronchoconstriction while inhibiting the proliferation of eosinophils in bronchoalveolar lavage (BAL) and their infiltration into the airway walls.

1,1'-Ethylidene-bis-(L-tryptophan) is a potential impurity in L-tryptophan commercial products, promoting EoL-3 eosinophilic leukemia cell proliferation, enhancing eosinophil cationic protein release from human peripheral blood eosinophils, and boosting IL-5 production in human T cells. At 40 µg/kg, it triggers fascia thickening, mast cell infiltration, inflammation, and fibrosis in mouse superficial adipose and panniculus carnosus tissues, serving as an eosinophilia-myalgia syndrome research model.

SHR-1703 is a long-acting humanized anti-IL-5 IgG1 monoclonal antibody. It selectively identifies and binds to IL-5, preventing IL-5 from associating with the α chain of eosinophil surface receptors. This action inhibits the proliferation, activation, and migration of eosinophils, ultimately reducing eosinophil-mediated inflammation and damage. SHR-1703 is applicable for research into eosinophil-related diseases, such as eosinophilic asthma. The recommended isotype control is HumanIgG1kappa, Isotype Control.